Amgen and AstraZeneca highlight data to be presented at 22nd congress of the European Academy of Dermatology and Venereology
Posted: 3 October 2013 | | No comments yet
“The Phase 2 data demonstrate that the primary and secondary end points were met…”
Amgen (NASDAQ: AMGN) and AstraZeneca (AZN), with its biologics research and development arm MedImmune, today announced the upcoming presentation of several key studies evaluating brodalumab, a human monoclonal antibody targeting the interleukin-17 (IL-17) receptor, for the treatment of moderate to severe psoriasis at the 22nd Congress of the European Academy of Dermatology and Venereology (EADV) in Istanbul, Oct. 2-6, 2013.
“The Phase 2 data demonstrate that the primary and secondary end points were met, including many patients achieving and maintaining total skin clearance with continued brodalumab therapy,” said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. “We look forward to further investigating brodalumab for patients with moderate to severe psoriasis.”
Dr. Bahija Jallal, executive vice president, MedImmune added, “We’re very encouraged by these results and the initiation of our Phase 3 program.
In Oct. 2012, the companies announced the start of the Phase 3 program in moderate to severe psoriasis for brodalumab. The program consists of three Phase 3 studies evaluating treatment with brodalumab compared with ustekinumab and/or placebo.
Abstracts will be presented during the poster session on Friday, Oct. 4, 2013.
Abstracts of Interest Include:
- Maintenance of Clinical Response with Long-Term Brodalumab (AMG 827) Therapy for Psoriasis: Week 96 Results from an Open-Label Extension Study (Poster IST13-0686)
- Difference in Health-Related Quality of Life (HRQoL) with Increased Improvements in Psoriasis Area and Severity Index (PASI) and Maintenance of Skin Clearance (Poster 1030)
- Impact of Treatment with Brodalumab on Psoriasis Symptom Severity: Use of a Novel Patient-Reported Outcome Measure, the Psoriasis Symptom Inventory (PSI) (Poster 1640)
About Brodalumab (AMG 827)
Brodalumab is a highly-selective human monoclonal antibody that binds to and blocks signaling via the interleukin-17 (IL-17) receptor. The IL-17 pathway plays an important role in inducing and promoting inflammatory disease processes. Blocking inflammatory signaling at the IL-17 receptor may be beneficial in the treatment of moderate to severe plaque psoriasis, psoriatic arthritis, and potentially other immune-mediated diseases.
